Re-Aim Therapeutics Ltd. has launched with £7 million (US$9.4 million) in seed investment backing and a focus on developing functional cures for T-cell-mediated autoimmune diseases.
Harbour Biomed has released preclinical data for LET-003, a next-generation ACVR2A/2B-targeted monoclonal antibody with potential for the treatment of obesity. Activin receptors ACVR2A and ACVR2B play critical roles in regulating muscle-fat metabolic homeostasis.
Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders.
The interleukin-1 receptor accessory protein (IL1RAP) is expressed in cancer cells within the tumor microenvironment of several cancer types and plays a role in tumor development. DXP-106 is a humanized monoclonal antibody developed by Singlomics Biopharmaceuticals Co. Ltd. that binds to a unique epitope of IL1RAP domain 2 that competes with cytokines.
Tumors with strong immunosuppressive microenvironments such as microsatellite-stable colorectal cancer (MSS-CRC) remain unresponsive to immune checkpoint blockade therapy, with <20% of gastrointestinal tumors responding to therapy.
Alethio Therapeutics Inc. has unveiled ATX-011, a mutation-agnostic antibody for essential thrombocythemia. ATX-011 is a potential first-in-class monoclonal antibody based on a new target identified on mutant stem cells that drive myeloproliferative neoplasm disease progression.
Invivyd Inc. has announced the discovery and advancement of VMS-063, a novel monoclonal antibody candidate for the treatment and prevention of measles.
Ibio Inc. has received clinical trial notification (CTN) acknowledgement from Australia’s Therapeutic Goods Administration (TGA), as well as Human Research Ethics Committee approval, for IBIO-600, enabling the initiation of a first-in-human trial in Australia.
At the World Vaccine Congress this week, Longhorn Vaccines & Diagnostics LLC presented the preclinical characterization of LHNVD-501, a half-life-extended, humanized IgG monoclonal antibody (mAb) targeting peptidoglycan (PGN). PGN is a conserved structural component shared across bacterial species and an upstream driver of sepsis, as well as metabolic disease, autoimmune disorders and neurodegeneration.
Tyligand Bioscience Ltd. has reported new dual-drug antibody-drug conjugates comprising monoclonal antibodies covalently linked to stimulator of interferon genes protein (STING; TMEM173) agonist and a cytotoxic drug.
RSS
